The NMP22Bladderchek urine test from Inverness Medical is claimed to be the only FDA-approved tumour marker for the diagnosis and aftercare of patients with bladder cancer.
Urinary bladder cancer is more likely to be fatal in women than in men.
With a male-to-female incidence ratio of approximately three to one, for women, the disease becomes fatal at a much earlier stage.
The relative five-year survival rate for women is 72 per cent - corresponding to a ten-year survival rate for men.
One of the reasons for the lower survival rate in women is inadequate early detection.
Screening for the disease can be performed with a simple proteomic test of a urine sample, such as the NMP22Bladderchek test from Inverness Medical, directly in the clinician's office.
